Growing community of inventors

Philadelphia, PA, United States of America

Pietro Mancuso

Average Co-Inventor Count = 7.00

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 3

Pietro MancusoVikram Bhattacharjee (3 patents)Pietro MancusoAlfonso Bellacosa (3 patents)Pietro MancusoRossella Tricarico (3 patents)Pietro MancusoLionel Larue (2 patents)Pietro MancusoTim Yen (2 patents)Pietro MancusoTimothy J Yen (1 patent)Pietro MancusoNeil Beeharry (1 patent)Pietro MancusoMitchell Smith (1 patent)Pietro MancusoIrwin Davidson (1 patent)Pietro MancusoIrwin Davidson (1 patent)Pietro MancusoIrwin Davidson (1 patent)Pietro MancusoPietro Mancuso (3 patents)Vikram BhattacharjeeVikram Bhattacharjee (8 patents)Alfonso BellacosaAlfonso Bellacosa (8 patents)Rossella TricaricoRossella Tricarico (3 patents)Lionel LarueLionel Larue (3 patents)Tim YenTim Yen (2 patents)Timothy J YenTimothy J Yen (7 patents)Neil BeeharryNeil Beeharry (3 patents)Mitchell SmithMitchell Smith (2 patents)Irwin DavidsonIrwin Davidson (1 patent)Irwin DavidsonIrwin Davidson (1 patent)Irwin DavidsonIrwin Davidson (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Institute for Cancer Research (2 from 64 patents)

2. Institut Curie (1 from 154 patents)

3. Institut De Genetique Et De Biologie Moleculaire Et Cellulaire (1 from 1 patent)

4. Institute for Cancer Research D/b/a the Research Institute of Fox Chase Cancer Center (0 patent)

5. Institut De Genetique Et De Biologie Moleculaire Et Cellularire (0 patent)


3 patents:

1. 11883413 - Inhibition of thymine DNA glycosylase in the treatment of cancer

2. 11077121 - Inhibition of thymine DNA glycosylase in the treatment of cancer

3. 10220051 - Combination of DNA repair inhibition with bendamustine or gemcitabine in the treatment of cancer

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/29/2025
Loading…